Dose Reconstruction Program

Lynn R. Anspaugh, Scientific Director (510) 424-6409 anspaugh1@llnl.gov

Sheilah M. Hendrickson, Executive Director (510) 424-6410 hendrickson3@llnl.gov

September 18, 1996

Dr. Faye Austin National Cancer Institute Executive Plaza North, Suite 500 6130 Executive Blvd. Bethesda, MD 20892-7362

Dear Dr. Austin:

Thank you for meeting with us on September 12. I regret the events that have led to our current situation, but I want to reiterate our desire to disassociate ourselves from the managers of your Radiation Effects Branch (REB). We desire to do this as completely as possible and as soon as possible.

As we mentioned before, we will not and cannot continue to be responsible for the purchase, delivery, and inventory of equipment and supplies for NCI/REBrelated activities in the absence of our scientific involvement and our ability to verify the location and use of such equipment and supplies. We have already completed the purchases for which we had clear approval from NCI/REB. Unfortunately, we still have some deliveries outstanding and several unpaid accounts; it will also take some time to ensure the proper receipt and accountability of the equipment that has been ordered and/or sent.

The situation with the scientific activities is more complicated, as we have unfinished papers, unfinished projects, and unfinished commitments with persons and organizations. We will be working with DOE and others to wrap up any such commitments during the course of the upcoming twelve months, and it is our desire not to undertake any future commitments connected with NCI/REB-related activities. We do, of course, and as discussed during our recent meeting, intend to pursue other activities with our friends and colleagues in Belarus, Ukraine, and Russia that are not related to the activities of your Radiation Effects Branch.



Dr. Faye Austin September 18, 1996 Page 2

One of the main purposes of this letter is to address an issue that we left on your table during the course of our meeting. This is the contract with the Russian dosimetrists, and whether the contract should be placed by LLNL, DOE, or NCI. Our basic position has been that it does not make sense for LLNL to continue with this contract in the absence of future scientific involvement in the project. Although Dr. Masnyk indicated that NCI knew nothing about this contract, the fact is that we have been working with Dr. Bouville of your staff since January in order to define the scope, milestones, and deliverables for this contract. Both Dr. Bouville and I feel strongly that the Moscow dosimetrists are essential for the success of the Belarus–US Thyroid Project, and that it is critical for the Moscow dosimetrists to be enjoined in the process now. On September 13 Ms. Hendrickson and I discussed this issue with Mr. Frank Hawkins of DOE. He was quite emphatic that DOE would not place this contract, but stated that he would be willing for us to place this contract.

I presume the issue is really one of timing, which we consider to be critical. If we hear from you by September 20, we believe that we could have this contract in operation by November 1, 1996. If you take the material that we have developed, and of which Dr. Bouville has copies, perhaps you could place the contract as quickly. If we don't hear from you by September 27, we will presume that you do not wish us to proceed in this matter.

If LLNL does place the contract, I hope it is understood completely that this will be an LLNL contract, and we will be fully responsible for its administration and the acceptance of deliverables. This would be counter to our desire for rapid disassociation, but we are willing to make an exception due to our concerns for the Moscow dosimetrists.

We hope that you will discuss this issue with Dr. Bouville.

Sincerely yours,

Lynn R. Anspaugh, Ph.D.

cc: André Bouville Elaine Gallin